Skip Nav Destination
Issues
15 June 2007
-
Cover Image
Cover Image
Tumor blood vessels are disorganized because of dysregulated angiogenesis. The investigators have shown that microvascular proliferation in neuroblastoma is significantly associated with Schwannian stroma–poor histology and worse outcome. These results provide further rationale for using antiangiogenic treatment strategies in clinically aggressive disease. The cover figure shows blood vessels with immunoflourescence double labeling of endothelial cells (red) and vascular mural cells (green). For further details, please see Peddinti et al. on page 3499 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
The Biology Behind
Molecular Pathways
CCR Focus
Human Cancer Biology
Imaging, Diagnosis, Prognosis
Gene Expression Signatures Predict Outcome in Non–Muscle-Invasive Bladder Carcinoma: A Multicenter Validation Study
Lars Dyrskjøt; Karsten Zieger; Francisco X. Real; Núria Malats; Alfredo Carrato; Carolyn Hurst; Sanjeev Kotwal; Margaret Knowles; Per-Uno Malmström; Manuel de la Torre; Kenneth Wester; Yves Allory; Dimitri Vordos; Aurélie Caillault; François Radvanyi; Anne-Mette K. Hein; Jens L. Jensen; Klaus M.E. Jensen; Niels Marcussen; Torben F. Ørntoft
Early Response Assessment Using 3′-Deoxy-3′-[18F]Fluorothymidine-Positron Emission Tomography in High-Grade Non-Hodgkin's Lymphoma
Ken Herrmann; Hinrich A. Wieder; Andreas K. Buck; Marion Schöffel; Bernd-Joachim Krause; Falko Fend; Tibor Schuster; Christian Meyer zum Büschenfelde; Hans-Jürgen Wester; Justus Duyster; Christian Peschel; Markus Schwaiger; Tobias Dechow
Bcl-2 and Bax Expression Predict Prostate Cancer Outcome in Men Treated with Androgen Deprivation and Radiotherapy on Radiation Therapy Oncology Group Protocol 92-02
Li Yan Khor; Jennifer Moughan; Tahseen Al-Saleem; Elizabeth H. Hammond; Varagur Venkatesan; Seth A. Rosenthal; Mark A. Ritter; Howard M. Sandler; Gerald E. Hanks; William U. Shipley; Alan Pollack
Cancer Therapy: Clinical
Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies
Suresh S. Ramalingam; Robert A. Parise; Ramesh K. Ramananthan; Theodore F. Lagattuta; Lori A. Musguire; Ronald G. Stoller; Douglas M. Potter; Athanassios E. Argiris; James A. Zwiebel; Merrill J. Egorin; Chandra P. Belani
Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor
Johann S. de Bono; Gerhardt Attard; Alex Adjei; Michael N. Pollak; Peter C. Fong; Paul Haluska; Luisa Roberts; Carrie Melvin; Madeline Repollet; David Chianese; Mark Connely; Leon W.M.M. Terstappen; Antonio Gualberto
Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor–Positive Patients
John F. Smyth; Charlie Gourley; Graeme Walker; Melanie J. MacKean; Alan Stevenson; Alistair R.W. Williams; Awatif Al Nafussi; Tzyvia Rye; Ron Rye; Moira Stewart; Janet McCurdy; Max Mano; Nick Reed; Tracey McMahon; Paul Vasey; Hani Gabra; Simon P. Langdon
An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma
Ian D. Davis; Birte K. Skrumsager; Jonathan Cebon; Theo Nicholaou; John W. Barlow; Niels Peter Hundahl Moller; Kresten Skak; Dorthe Lundsgaard; Klaus Stensgaard Frederiksen; Peter Thygesen; Grant A. McArthur
A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors
Jens Voortman; Egbert F. Smit; Richard Honeywell; Bart C. Kuenen; Godefridus J. Peters; Helgi van de Velde; Giuseppe Giaccone
A Randomized, Double-Blind, Phase II Study of Two Doses of Pemetrexed as First-Line Chemotherapy for Advanced Breast Cancer
Antonio Llombart-Cussac; Miguel Martin; Nadia Harbeck; Rodica M. Anghel; Alexandra E. Eniu; Mark W. Verrill; Patrick Neven; Jacques De Grève; Allen S. Melemed; Romnee Clark; Lorinda Simms; Christopher J. Kaiser; Doreen Ma
Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study
Timothy W. Synold; Chris H. Takimoto; James H. Doroshow; David Gandara; Sridhar Mani; Scot C. Remick; Daniel L. Mulkerin; Anne Hamilton; Sunil Sharma; Ramesh K. Ramanathan; Heinz Josef Lenz; Martin Graham; Jeffrey Longmate; Bennett M. Kaufman; Percy Ivy
Cancer Therapy: Preclinical
AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis
Robert W. Wilkinson; Rajesh Odedra; Simon P. Heaton; Stephen R. Wedge; Nicholas J. Keen; Claire Crafter; John R. Foster; Madeleine C. Brady; Alison Bigley; Elaine Brown; Kate F. Byth; Nigel C. Barrass; Kirsten E. Mundt; Kevin M. Foote; Nicola M. Heron; Frederic H. Jung; Andrew A. Mortlock; F. Thomas Boyle; Stephen Green
[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor–Targeted Therapy for Insulinoma
Andreas Wicki; Damian Wild; Daniel Storch; Christian Seemayer; Martin Gotthardt; Martin Behe; Stefan Kneifel; Michael J. Mihatsch; Jean-Claude Reubi; Helmut R. Mäcke; Gerhard Christofori
Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647
Steven B. Gendreau; Richard Ventura; Paul Keast; A. Douglas Laird; F. Michael Yakes; Wentao Zhang; Frauke Bentzien; Belinda Cancilla; Jeffery Lutman; Felix Chu; Lisa Jackman; Yongchang Shi; Peiwen Yu; Jing Wang; Dana T. Aftab; Christopher T. Jaeger; Stephanie M. Meyer; Anushka De Costa; Kelly Engell; Jason Chen; Jean-Francois Martini; Alison H. Joly
Cancer Prevention
Lack of an Association between the TGFBR1*6A Variant and Colorectal Cancer Risk
Johanna Skoglund; Bo Song; Johan Dalén; Stefan Dedorson; David Edler; Fredrik Hjern; Jörn Holm; Claes Lenander; Ulrik Lindforss; Nils Lundqvist; Hans Olivecrona; Louise Olsson; Lars Påhlman; Jörgen Rutegård; Kennet Smedh; Anders Törnqvist; Richard S. Houlston; Annika Lindblom
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds